Sanofi (SNY) EBIT Margin (2009 - 2026)

Sanofi has disclosed EBIT Margin across 18 years of filings, most recently posting 20.18% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 20.18%, down 291.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.0% (down 697.0% YoY), and the FY2025 annual result was 14.54%, down 311.0% from the prior year.
• EBIT Margin came in at 20.18% for Q1 2026 at Sanofi, down from 55.87% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 55.87% in Q4 2025 to a low of 8.91% in Q4 2024.
• The 5-year median for EBIT Margin is 21.82% (2022), against an average of 22.92%.
• Across the five-year window, EBIT Margin plunged 2210 bps in 2023 and surged 4696 bps in 2025, its largest moves.
• Sanofi's EBIT Margin stood at 38.26% in 2022, then slumped by 58 bps to 16.16% in 2023, then tumbled by 45 bps to 8.91% in 2024, then soared by 527 bps to 55.87% in 2025, then tumbled by 64 bps to 20.18% in 2026.
• The last three EBIT Margin figures came in at 20.18% (Q1 2026), 55.87% (Q4 2025), and 22.84% (Q3 2025), per Business Quant data.